Dasatinib while targeting several other kinases (including BCR-ABL, cKIT, PDGFR, and SRC family kinases) has the advantage of being an FDA and EMA approved drug for the treatment of chronic myeloid leukaemia (CML) with a good oral bioavailability. This evidence concerns the gene SRC and chronic myelogenous leukemia, BCR-ABL1 positive.